Overview

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate